Early Alirocumab to Reduce LDL-C in Myocardial Infarction
Status:
Withdrawn
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The EARLY trial is a phase IV, investigator initiated, international, multicentre study that
will investigate if early use of alirocumab 150mg plus atorvastatin 80mg (enhanced care) will
have a greater effect than atorvastatin 80mg (standard care) on the reduction of LDL-C at
2-weeks after a myocardial infarction (MI), in patients who start treatment within 24 hours
of symptom onset.
A secondary goal is to assess the effects of enhanced care when compared to standard care
which is either atorvastatin alone or atorvastatin plus ezetimibe, (the latter added at 4
weeks if LDL-C is ≥ 70mg/dL (1.8mmol/L), on the proportion of patients achieving an LDL-C
goal of < 50mg/dL (1.29 mmol/L) at 7 weeks after an MI.
Phase:
Phase 4
Details
Lead Sponsor:
Imperial College London
Collaborators:
Baim Institute for Clinical Research Regeneron Pharmaceuticals